PREP Inhibitors for Lung Inflammation in COPD
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic obstructive pulmonary disease (COPD) primarily focus on symptom management and are limited in addressing the underlying inflammatory processes, with no effective cure available, and existing medications have significant side effects due to immunomodulatory actions.
Innovation Solution
Development of novel low molecular weight compounds that inhibit prolyl endopeptidase (PREP), reducing the production of proline-glycine-proline (PGP), a key mediator in lung inflammation, thereby decreasing neutrophil recruitment and inflammation in COPD and other inflammatory disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If conventional immunomodulatory medications are used to treat COPD, then inflammatory processes are suppressed, but significant side effects occur
Solution Approach 1:
The patent uses selective PREP inhibition as an intermediary mechanism to reduce PGP levels, which in turn decreases neutrophil recruitment and inflammation. This indirect approach avoids direct immunomodulation and its associated side effects, targeting the specific inflammatory pathway through PGP-PREP interaction rather than broad immune suppression
Solution Approach 2:
The invention changes the biochemical parameter of PGP concentration by selectively inhibiting PREP enzyme activity. This specific parameter change (reducing PGP levels) achieves anti-inflammatory effects without the non-specific immunomodulatory actions that cause side effects in conventional treatments
2Ease of operation
If symptom management treatments are used for COPD, then patient symptoms are relieved, but the underlying inflammatory processes are not addressed
Solution Approach 1:
The patent applies preliminary action by targeting and reducing PGP levels before they can fully drive neutrophil recruitment and inflammatory cascades. By inhibiting PREP early in the inflammatory pathway, the treatment prevents the full development of inflammatory processes rather than merely managing their symptoms
Solution Approach 2:
The invention extracts and targets the specific inflammatory mediator PGP from the complex inflammatory pathway. By selectively removing or reducing PGP through PREP inhibition, the treatment addresses the root inflammatory driver rather than treating downstream symptoms
Data Source
AI summary
The present application relates to novel substituted 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridin-3(2H)-ones and 2,5,6,7-tetrahydro-3H-pyrrolo[2,1-c][1,2,4]triazol-3-ones of formula (I), to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of lung inflammation disorders.